Biocon Limited — Updates, 27-06-2025: Press Release

Biocon Biologics has announced a board meeting to approve the financial results for the quarter and half-year. The company received Health Canada approval for Yesafili™ (aflibercept), a biosimilar to Eylea®, marking its first global launch in Canada. This is Biocon Biologics’ 10th biosimilar commercialization, expanding affordable biologic options for retinal diseases in the Canadian market. The approval supports its global biosimilar growth with a strong pipeline across multiple therapeutic areas. This milestone underlines Biocon’s focus on innovation and global market expansion.